HLA-B*5701筛查十年间阿巴卡韦超敏反应报告率分析
该研究通过荟萃分析12项试验、OPERA队列及自发报告数据,评估HLA-B*5701筛查对阿巴卡韦超敏反应发生率的影响。结果显示HLA-B*5701阴性患者中疑似超敏反应率≤1.3%,2008年后OPERA队列发生率为0.4% vs 2008年前1.3%(p<0.0001),自发报告率亦显著下降。结论认为筛查降低了临床实践中疑似超敏反应报告率。
要点
- HLA-B*5701阴性患者中阿巴卡韦疑似超敏反应率≤1.3%。
- OPERA队列2008年后发生率为0.4%,显著低于2008年前的1.3%(p<0.0001)。
- 筛查为标准实践处,启用阿巴卡韦前应确认HLA-B*5701阴性。
核心结论
- HLA-B*5701阴性患者中临床疑似阿巴卡韦超敏反应率≤1.3%。
- OPERA队列和自发报告数据表明HLA-B*5701筛查降低了临床实践中疑似超敏反应报告率。
研究设计与样本
- 荟萃分析纳入12项试验、3063例HLA-B*5701阴性接受含阿巴卡韦方案患者(2007年4月9日至2015年9月22日)。
- OPERA队列纳入9619例首次启动含阿巴卡韦方案患者(1999年1月1日至2016年1月1日),观察至停药、失访、死亡或研究结束(2016年7月31日)。
- 利用四种上市含阿巴卡韦产品的自发报告数据,通过销售数据估算暴露量,计算报告率至2016年12月31日。
主要发现
- 荟萃分析中疑似阿巴卡韦超敏反应率≤1.3%。
- OPERA队列2008年后启动阿巴卡韦者发生率为0.4%,2008年前为1.3%(p<0.0001)。
- 自发报告率2008年后为54至22例/10万患者年暴露,2008年前为618至55例/10万患者年暴露。
临床怎么用
- 在HLA-B*5701筛查为标准实践的地区,启用阿巴卡韦前应确认患者该等位基因阴性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus treatment guidelines in 2008. Company meta-analyses of trials pre-HLA-B*5701 screening reported HSR rates of 4-8%. We analyzed the effectiveness of HLA-B*5701 screening on reducing HSR rates using clinical trial, Observational Pharmaco-Epidemiology Research & Analysis (OPERA) cohort, and spontaneous reporting data. METHODS: A meta-analysis examined 12 trials in 3063 HLA-B*5701-negative patients receiving an ABC-containing regimen from April 9, 2007, to September 22, 2015. Potential cases were identified using prespecified Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (drug hypersensitivity, hypersensitivity, anaphylactic reaction, anaphylaxis) and adjudicated against a Company ABC HSR case definition. Investigator-diagnosed cases were identified and rates were calculated. In the OPERA cohort, 9619 patients initiating their first ABC-containing regimen from January 1, 1999, to January 1, 2016, were identified. Patients were observed from regimen start until the earliest-following censoring event: ABC discontinuation, loss to follow-up, death, or study end (July 31, 2016). OPERA physicians evaluated events against OPERA definitions for definite/probable cases of ABC HSR; rates were calculated pre- and post-2008. The Company case definition was used to identify spontaneously reported cases for four marketed ABC-containing products; reporting rates were calculated using estimated exposure from sales data, through December 31, 2016. RESULTS: Suspected ABC HSR rates were 1.3% or less in the meta-analysis. In the OPERA cohort, the rate was 0.4% among patients initiating ABC post-2008 versus 1.3% pre-2008 (p<0.0001). Spontaneous reporting rates were low post-2008 (54 to 22 cases per 100,000 patient-years exposure [PYE]) versus pre-2008 (618 to 55 cases per 100,000 PYE). CONCLUSIONS: Clinically suspected ABC HSR rates were 1.3% or less in HLA-B*5701-negative patients. Recognizing their limitations, data from the OPERA cohort and spontaneous reporting indicate that HLA-B*5701 screening has reduced reporting rates of suspected HSR in clinical practice. Where screening for HLA-B*5701 is standard care, patients should be confirmed negative for this allele before starting ABC treatment.
引用
- Stainsby CM, Perger TM, Vannappagari V, et al. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. Pharmacotherapy. 2018. PMID: 30414209. doi:10.1002/phar.2196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。